Document is current
Any future updates will be listed below
-
Authors
Wang, Qian-Ting
Nie, Ying
Sun, Sheng-Nan
Lin, Tao
Han, Ru-Jin
Jiang, Jun
Li, Zhe
Li, Jun-Qi
Xiao, Yun-Peng
Fan, Yu-Ying
Yuan, Xiao-Hui
Zhang, Hui
Zhao, Bin-Bin
Zeng, Ming
Li, Shi-You
Liao, Hua-Xin
Zhang, Jian
He, You-Wen https://orcid.org/0000-0002-8983-2684
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02709616 at ClinicalTrials.govnct02808364 at ClinicalTrials.govDocuments that mention this clinical trial
Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients
https://doi.org/10.1007/s00262-020-02496-w
nct02808416 at ClinicalTrials.govDocuments that mention this clinical trial
Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients
https://doi.org/10.1007/s00262-020-02496-w
Documents that mention this clinical trial
Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients
https://doi.org/10.1007/s00262-020-02496-w
-
Funding
Funding for this research was provided by:
Beijing Tricision Biotherapeutics Inc
- License Information
-
More Information
Article History
Received: 28 October 2019
Accepted: 20 January 2020
First Online: 20 February 2020
Compliance with ethical standards
:
: You-Wen He is a co-founder of Beijing Tricision Biotherapeutics. Huaxin Liao is a co-founder of Guangzhou Trinomab Inc. Shi-You Li is a co-founder of Beijing Tricision Biotherapeutics Inc. Sheng-Nan Sun and Jun Jiang are full-time employees of Beijing Tricision Biotherapeutics Inc. Yun-Peng Xiao is full-time employee of Guangzhou Trinomab Biotechnology Inc.
: Written informed consent was obtained from all patients before any of the study procedures were conducted. This study was approved by Jinan University Affiliated Guangdong 999 Brain Hospital Ethical Committee. All treatment procedures were performed in accordance with the ethical standards of the institutional and/or national research regulations and with the Helsinki declaration ethical standards. The study protocols are 1. “Personalized cellular vaccine for advanced solid tumors with brain metastases” (ID#:2015006). 2. “Personalized cellular vaccine for newly diagnosed glioblastoma multiforme” (ID#:2015001). 3. “Personalized cellular vaccine for recurrent glioblastoma multiforme” (ID#:2016007).
